跳至主要内容
临床试验/NCT01522170
NCT01522170终止不适用

An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study

Alexion Pharmaceuticals, Inc.55 个研究点 分布在 10 个国家目标入组 94 人开始时间: 2012年3月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
94
试验地点
55
主要终点
TMA complication-free survival

研究概览

简要总结

There is growing but limited information on the long term clinical status of aHUS patients who have previously received or are continuing to receive treatment with eculizumab. This study is designed to collect clinical data that will provide insight into the long-term outcomes of patients with aHUS.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Other

入排标准

性别
All
接受健康志愿者

入选标准

  • aHUS patients who participated in any one of the aHUS-eculizumab clinical studies.
  • aHUS patients or legal representative who are able and willing to given written informed consent for their study information to be collected and retained in a database.

排除标准

  • Not applicable.

结局指标

主要结局

TMA complication-free survival

时间窗: 5 Years

Assess the long term efficacy of eculizumab in patients with aHUS who have previously participated in an eculizumab clinical study.

次要结局

  • Duration of response, change over time of value for platelets, LDH, eGFR, Hgb, TMA intervention(5 Years)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (55)

Loading locations...

相似试验